Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals, Inc. - Common Stock
(NQ:
ALNY
)
322.38
-1.21 (-0.37%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
15
16
17
18
19
20
21
22
Next >
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
↗
April 24, 2021
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...
Via
Benzinga
Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran
April 19, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs
↗
April 17, 2021
The FDA and CDC announced their recommendation to pause the use of Johnson & Johnson's JNJ COVID-19 vaccine following incidences of severe clots. J&J's pain turned into gains for other COVID-19 vaccine...
Via
Talk Markets
The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs
↗
April 17, 2021
Biotech stocks reversed course in the week ended April 16, with the sector rebounding along with the broader market. The week's news flow was fairly light. The American...
Via
Benzinga
Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results
April 15, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
April 11, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront
↗
April 08, 2021
Royalty Pharma plc (NASDAQ: RPRX) has acquired Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an...
Via
Benzinga
< Previous
1
2
...
15
16
17
18
19
20
21
22
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
